临床试验

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

NCT：NCT05403723 · SUSPENDED

NCT编号NCT05403723

状态SUSPENDED

开始日期2027-01-30

SponsorUniversity of Maryland, Baltimore (OTHER)

First posted2022-06-03

Last updated2026-09-14

简要摘要

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。